RBC Capital lowered the firm’s price target on Genmab (GMAB) to DKK 2,000 from DKK 2,300 and keeps an Outperform rating on the shares. The firm is updating its model after Q1 results, with minimal underlying changes but now incorporating an updated USD-DKK exchange rate which significantly lowers royalty income on U.S. sales in DKK terms, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Executes Share Buy-back Transactions in May 2025
- Genmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results
- Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment
- Genmab A/S Updates Articles to Enhance Capital Flexibility
- Genmab Announces Capital Increase Following Employee Warrant Exercise
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue